Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a blood pressure boost save brain cells during a stroke?

NCT ID NCT04218773

Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused This study
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This pilot study tests whether temporarily raising blood pressure with drugs like phenylephrine or norepinephrine can reduce brain damage in people having a major stroke. About 40 adults with large-vessel blockage strokes will receive the blood pressure boost during standard clot-removal procedures. The main goals are to see if the approach is feasible and safe, not yet to prove it works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Phenylephrine or Norepinephrine (blood pressure-raising drugs)
What this could lead to
If it works, this could point toward a simple way to reduce brain damage during stroke treatment by temporarily boosting blood pressure.
What could go wrong
This is a very early, small pilot study (40 people) that is currently suspended. Raising blood pressure in stroke patients carries risks like bleeding or heart problems, and the approach may not prove safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2020

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age is ≥18 years 2. Patients presenting with anterior circulation acute ischemic stroke 3. Enrollment within 24 hours of stroke onset 4. Treatment with endovascular thrombectomy 5. Arterial occlusion on CTA or MRA of the ICA, M1 or M2 6. Mismatch - Using CT or MRI with a Tmax \>6 second delay perfusion volume and either CT-rCBF or DWI infarct core volume. 1. Mismatch ratio of greater than 1.8, and 2. Absolute mismatch volume of greater than 15 ml, and 3. Infarct core lesion volume of less than 70 mL Exclusion Criteria: 1. Baseline SBP\>200 mm Hg 2. Intracranial hemorrhage (ICH) identified by CT or MRI 3. Inability to access the cerebral vasculature in the opinion of the neurointerventional team 4. Contraindication to imaging with MR 5. A history of a left ventricular heart failure (NYHA Class ≥ III, or EF \< 50%) or angina (either unstable or CCS Grade II) involving symptoms at rest or with ordinary physical activity 6. Acute myocardial infarction in the past 6 months 7. Signs or symptoms of acute myocardial infarction, including electrocardiogram find-ings, on admission 8. Elevated serum troponin concentration on admission (\>0.1 μg/L) 9. Suspicion of aortic dissection on admission 10. Participation in any investigational study in the previous 30 days 11. Treatment with Monoamine oxidase inhibitors (MAO-I) within last 7 days

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blood pressure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertensive disorder ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Blood pressure Ischemic stroke

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Yale-New Haven Hospital

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.